Endocyte stock sinks due to possible drug-filing delay

Back to TopCommentsE-mailPrintBookmark and Share

Endocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application for U.S. approval of a cancer treatment could be delayed another 10 months.

West Lafayette-based Endocyte is developing an ovarian cancer drug called vintafolide, which would be the first new drug approved to treat the painful cancer in more than a decade.

Its shares fell to as low as $8.50 each in morning trading after the company released fourth-quarter financial results Monday following the close of financial markets.

Endocyte has applied for approval of vintafolide in Europe, at the encouragement of regulators there, even before it completed a Phase 3 clinical trial.

But, in the United States, Endocyte will need to complete its Phase 3 trial before the Food and Drug Administration will consider it for market approval.

That Phase 3 trial was supposed to end in the first half of 2014 but now may last another nine to 10 months.

That’s because Endocyte and its development partner, New Jersey-based Merck & Co. Inc., have lined up a plan to test 100 extra patients next year in order to have better data on vintafolide’s ability to prolong patients’ lives.

As it stands, Endocyte’s Phase 3 trial of vintafolide will include just 250 patients and is designed to measure only the amount of time the drug extends the time in which patients have no regression of ovarian cancer.

But the FDA has been increasingly interested in seeing cancer drugs not only improve patients’ progression-free survival timelines, but also to lengthen their lives, which is called overall survival, or OS.

“I think it’s safe to say that we have a much, a better chance, of course, of hitting an OS endpoint at 350 [patients] than we do at 250,” Endocyte CEO Ron Ellis told Wall Street analysts during a conference call Monday evening.

The downside of that decision is that it delays the timeline for potential approval of vintafolide in the United States.

Endocyte has no products on the market, and is slowly burning through cash it raised via two public offerings in 2011.

The company had more than $200 million in cash on hand at the end of 2012, but expects to spend $65 million in 2013.

Much of Endocyte’s research on vintafolide is supported by Merck, which now includes studies in lung and breast cancer. For example, Merck will pay 75 percent of the costs of enrolling the extra 100 patients in Endocyte's ovarian cancer study. Merck has also committed to help Endocyte commercialize the drug in Europe.

The companies expect to receive a decision from European regulators on whether vintafolide can be sold there by the end of 2013.

In the fourth quarter of 2012, Endocyte lost $849,000, or 2 cents per share, on revenue of $14.5 million, most of which came from Merck.

For all of 2012, Endocyte lost $17.3 million, or 48 cents per share, an improvement from the previous year’s loss of $40.5 million, or $1.40 per share.

Its full-year revenue totaled $34.7 million, compared with $191,000 in the previous year.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.